DP
ALNY icon

Diadema Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Diadema Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$5.4M – 97
2025
Q1 		$5.4M Buy
+20,000
New +$5.14M 1.41% 20

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Diadema Partners's ALNY Position: Q1 2026 in Review

Diadema Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 5,341 shares — an estimated $2.12M sold.

Diadema Partners first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $4.56M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Diadema Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Diadema Partners sold 5,341 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.12M.
  • Diadema Partners first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Diadema Partners's Alnylam Pharmaceuticals position peaked at $4.56M in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.